U.S. Pharma Stock News

AI expansion and data center buildout reshape the Hut 8 story Hut 8 (HUT) is in focus after CEO Asher Genoot outlined a US$7b push into AI infrastructure, including the Riverbend campus buildout and plans for future gigawatt scale data centers. See our latest analysis for Hut 8. The recent commentary around Hut 8’s US$7b AI buildout comes after a period where the share price has seen a 10.94% 1 month share price decline. However, the stock has also delivered a very large 1 year total...

Brown-Forman (NYSE:BF.B) and Pernod Ricard have confirmed they are in talks over a potential merger of equals. The contemplated combination would bring together two large global spirits groups with extensive brand portfolios. Both companies have acknowledged that discussions are ongoing and no definitive agreement has been reached. For Brown-Forman, with a recent share price around $27.19, confirmed merger talks arrive after a mixed share performance picture. The stock is up 19.3% over the...

Why Lemonade Is Back on Investors’ Radar Lemonade (LMND) has drawn fresh investor attention after favorable commentary on a popular finance show, coupled with its recent addition to the NASDAQ Internet Index, put the AI focused insurer back in the spotlight. See our latest analysis for Lemonade. The recent TV spotlight and NASDAQ Internet Index inclusion have arrived after a mixed stretch, with a 1 month share price return of 17.32% contrasting with a 20.09% share price decline year to date...

Why Axos Financial is on investors' radar Axos Financial (AX) has drawn fresh attention after recent trading left the stock with a one day return of about a 2.3% decline, alongside negative moves over the past month and past 3 months. See our latest analysis for Axos Financial. While the recent 1 month share price return of a 4.4% decline and year to date decline of 5.1% point to fading short term momentum, the 1 year total shareholder return of 30.6% and 3 year total shareholder return of...

In March 2026, Alliant Energy Corporation filed a follow-on equity offering to raise US$1.00 billion through an at-the-market issuance of common stock. This move signals a major step to bolster the company’s capital base, with potential implications for shareholder dilution and future funding flexibility. Next, we’ll examine how this US$1.00 billion at-the-market equity program could reshape Alliant Energy’s investment narrative and capital allocation outlook. This technology could replace...

Disc Medicine announced that it has now randomized and dosed the last participant in its pivotal, expanded 183-patient Phase 3 APOLLO trial of bitopertin in erythropoietic protoporphyria and X-linked protoporphyria, with top-line data expected in the fourth quarter of 2026 and an FDA decision anticipated by mid-2027. The trial’s enlargement from 150 to 183 patients, driven by patient and physician demand, underlines meaningful engagement with a potential first disease-modifying therapy for...

A recent insider purchase by director Celina J. Wang Doka, alongside a newly authorized US$100 million share repurchase program at F&G Annuities & Life (FG), has put fresh attention on the insurer's stock. See our latest analysis for F&G Annuities & Life. At around US$24.20, FG’s 6.84% 1 month share price return contrasts with a 25.10% 3 month share price decline and a 29.03% 1 year total shareholder return loss. This means recent buying interest follows a weak stretch where confidence has...

Silicon Motion Technology (NasdaqGS:SIMO) has introduced a new lineup of enterprise SSD controllers and storage solutions at NVIDIA GTC 2026. The products are designed for NVIDIA AI platforms, targeting AI inference workloads and high-density, low-latency storage architectures. The launch highlights the company’s focus on storage solutions for high-performance, scalable AI infrastructure. For investors watching the AI infrastructure build out, this move places Silicon Motion Technology...

Wondering if MGM Resorts International at around US$36.32 is a bargain or just fairly priced? This article walks through what the current share price might be telling you about value. The stock has returned 2.7% over the last 7 days, while the 1-year return sits at 19.6% and the year-to-date move is a 0.5% decline, with longer 3- and 5-year periods also showing declines. Recent coverage has focused on MGM Resorts International as a key player in global gaming and hospitality, with attention...

In March 2026, GDS Holdings Limited reported past fourth-quarter 2025 revenue of CNY 2,921.7 million, up from CNY 2,690.66 million, alongside a net loss of CNY 467.05 million versus prior-year net income of CNY 4.19 billion, while full-year 2025 revenue rose to CNY 11.43 billion and net income decreased to CNY 949.64 million from CNY 3.43 billion. At the same time, management projected 2026 total revenue between CNY 12.4 billion and CNY 12.9 billion and analysts lifted earnings estimates,...

QUALCOMM stock performance overview QUALCOMM (QCOM) has drawn attention after a period of weaker share performance, with the stock showing a 2.6% decline over the past day and deeper pullbacks over the past month and past 3 months. See our latest analysis for QUALCOMM. At a share price of US$127.11, QUALCOMM’s recent 1 month and year to date share price returns show a clear loss of momentum, even though the 3 year total shareholder return remains positive. Recent moves suggest investors are...

AGNC Investment at a glance AGNC Investment (AGNC) has attracted attention after a recent pullback, with the share price at $9.69 and negative returns over the past month and past 3 months contrasting with a positive 1 year total return. See our latest analysis for AGNC Investment. Recent trading has been weak, with the 1 month share price return of AGNC Investment at a 13.56% decline and the year to date share price return at an 11.34% decline, even as the 1 year total shareholder return...

On 19 March 2026, LivaNova announced that the FDA granted premarket approval for its aura6000 System, a proximal hypoglossal nerve stimulation therapy for adult patients with moderate to severe obstructive sleep apnea who cannot use or benefit from first-line treatments like positive airway pressure. Backed by the rigorously designed OSPREY randomized controlled trial and plans for an MRI‑compatible, rechargeable next‑generation device, this approval opens a new neuromodulation avenue for...

Amgen (NasdaqGS:AMGN) released new VESALIUS-CV Phase 3 subgroup data on Repatha showing a significant reduction in first major cardiovascular events in high risk patients with diabetes. The results indicate that Repatha, used alongside statins or other LDL C lowering therapies, may support earlier intervention for patients without diagnosed atherosclerosis. These findings position Repatha as the only PCSK9 inhibitor with evidence across both primary and secondary prevention settings. For...

Why Great Lakes Dredge & Dock (GLDD) is on investors’ radar today Great Lakes Dredge & Dock (GLDD) has drawn fresh attention after a period of strong longer term share performance, including a past 3 months total return of 29.1% and a 1 year total return of 91.9%. See our latest analysis for Great Lakes Dredge & Dock. At a share price of $16.97, recent momentum has come through a strong 90 day share price return of 29.2% and a 1 year total shareholder return of 92%, pointing to improving...

If you are wondering whether OneMain Holdings at around US$51.55 is offering fair value or a potential bargain, it helps to step back and look at the full valuation picture before making any decisions. The stock shows mixed recent returns, with a 0.1% move over the last 7 days, a 6.3% decline over 30 days, a 25.4% decline year to date, a 14.9% gain over 1 year, 79.3% over 3 years, and 48.9% over 5 years. Recent news coverage around OneMain Holdings has largely focused on its position within...

If you are wondering whether Venture Global's current share price reflects its real worth, this article walks through the key numbers behind the stock. Over shorter periods the stock has been active, with returns of 10.9% over 7 days, 80.9% over 30 days, 149.0% year to date and 77.3% over the last year. These movements can affect how investors think about both upside potential and risk. Recent attention around Venture Global has centered on its role in the energy sector and how investors are...

SentinelOne (S) has drawn fresh attention after announcing a multi-year collaboration with Google Cloud, a global partnership with LevelBlue, and new AI-focused security offerings showcased at RSA Conference 2026. See our latest analysis for SentinelOne. Despite the Google Cloud collaboration, LevelBlue partnership, and new AI offerings showcased at RSA, SentinelOne’s recent momentum has been weak, with a 90-day share price return of 16.3% and a 1-year total shareholder return of 33.2%. If...

Bit Digital (BTBT) has just posted its FY 2025 numbers with Q4 total revenue of US$33.4 million and a basic EPS loss of US$0.58, set against trailing twelve month revenue of US$113.6 million and a TTM basic EPS loss of US$0.31. Over recent quarters the company has seen quarterly revenue move from US$25.6 million in Q4 2024 to US$33.4 million in Q4 2025. Basic EPS has swung between a loss of US$0.32 in Q1 2025 and a profit of US$0.48 in Q3 2025 before returning to a loss in Q4, leaving...

If you are wondering whether Wix.com is attractively priced or still has more risk baked in than reward, the starting point is understanding what the current share price actually implies. The stock recently closed at US$87.14, after a sharp 23.7% gain over the last 30 days that sits against a 47.6% decline over the past year and a 70.3% decline over five years. That kind of rebound after a long stretch of weaker returns often comes after fresh information, such as changes in sentiment around...

Eli Lilly (NYSE:LLY) reported Phase 3b TOGETHER-PsA data showing that Taltz combined with Zepbound outperformed Taltz alone in adults with both active psoriatic arthritis and obesity. The trial represents the first time a dual-targeted approach has shown efficacy in this comorbid population, linking an immunology therapy with a metabolic drug in one regimen. The findings create a potential path toward label expansion for both medicines and may influence future treatment standards for...

Why Bristol-Myers Squibb (BMY) is on investors’ radar Bristol-Myers Squibb (BMY) is drawing attention after recent share price moves, with the stock showing a mix of short term pressure and longer term resilience that invites a closer look at its fundamentals. See our latest analysis for Bristol-Myers Squibb. At a share price of US$58.54, Bristol-Myers Squibb has seen a 1 day share price decline of about 1.5%, alongside a 9.5% year to date share price return and a 12.6% five year total...

Earlier this month, Entergy Louisiana disclosed a major agreement under which Meta Platforms will finance ten natural gas plants, around 240 miles of high-voltage transmission lines, grid-scale battery storage, and nuclear uprates to power Meta’s Hyperion data center in rural Louisiana while covering its full cost of service. The deal’s structure, which is expected to deliver more than US$2.00 billion in ratepayer savings over two decades, highlights how tailored utility-customer...

Kish Bancorp (KISB) just turned in its FY 2025 numbers with fourth quarter revenue of US$18.9 million and basic EPS of US$1.84, alongside trailing twelve month revenue of US$70.3 million and EPS of US$6.25 that frame the full year picture. Over the past few quarters, revenue has moved from US$15.8 million in Q3 2024 to US$18.9 million in Q4 2025, while quarterly EPS has gone from about US$1.39 to US$1.84. This sets up a results season where margins and earnings quality are front and center...